Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

PhRMA Statement on India Supreme Court Decision on Glivec
WASHINGTON, D.C. (April 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “PhRMA is very disappointed with the Indian Supreme Court’s decision to deny a patent on Glivec. This decision marks yet another example of the deteriorating innovation environment in India.  Innovation is critical in meeting unmet needs of patients and is particularly relevant in the context of changing healthcare systems. In order to solve the real health challenges of India’s patients, it is critically important that India promote a policy environment that supports continued research and development of new medicines for the health of patients in India and worldwide. Protecting intellectual...
Read more

Latest Releases

PhRMA Statement on Proposal for an Alternative Approval Pathway for Certain Drugs Intended to Address Unmet Medical Need
2/28/2013
WASHINGTON, D.C. (February 28, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President of Scientific & Regulatory Affairs Sascha Haverfield issued the following statement today regarding the proposal to create a potential new drug approval pathway intended to expedite the development of new medicines for serious or life-threatening conditions that would address an unmet medical need, including medicines for serious or life-threatening infections caused by antibiotic-resistant bacteria:
More
PhRMA Statement on Time Magazine Article
2/21/2013
WASHINGTON, D.C. (February 21, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement: “Today’s Time Magazine article focuses exclusively on costs, overlooking the tremendous value that innovative medicines deliver to patients and the health care system for only a small fraction of overall health spending. Across the spectrum of diseases, medications have significantly improved quality and length of life.
More
PhRMA Statement on Human Brain Mapping Initiative
2/19/2013
WASHINGTON, D.C. (February 18, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today regarding a new initiative by the Administration that could help further medical research for neurological diseases:
More
Statement to State of the Union Address
2/13/2013
More
PhRMA and EFPIA Applaud Push for EU-US Trade Agreement
2/13/2013
More
Virginia Research Institutions Conducted Over 3,400 Clinical Trials of New Medicines Since 1999
2/11/2013
Governor McDonnell Stresses Vital Biopharmaceutical Research
WASHINGTON, D.C. (February 11, 2013) – Working in collaboration with university medical schools and science centers, local hospitals and clinical research facilities, America’s biopharmaceutical companies have conducted 3,412 clinical trials of new medicines in Virginia over the last 13 years, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). The report – “Research in Your Backyard: Pharmaceutical Clinical Trials in Virginia” – was released today at a news conference with Governor Robert McDonnell and Keenan Caldwell, state government relations director of the American Cancer Society Cancer Action Network in Virginia, in the West Reading Room of the Patrick Henry Building.
More

Subscribe to our Email Updates